Aliases & Classifications for Melanoma

MalaCards integrated aliases for Melanoma:

Name: Melanoma 12 37 29 55 6 43 44 15 63 40 73
Malignant Melanoma 12
Cutaneous Melanoma 73
Naevocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1909
MeSH 44 D008545
NCIt 50 C3224
KEGG 37 H00038
ICD10 33 D03.9
UMLS 73 C0025202

Summaries for Melanoma

MedlinePlus : 43 Melanoma is the most serious type of skin cancer. Often the first sign of melanoma is a change in the size, shape, color, or feel of a mole. Most melanomas have a black or black-blue area. Melanoma may also appear as a new mole. It may be black, abnormal, or "ugly looking." Thinking of "ABCDE" can help you remember what to watch for: Asymmetry - the shape of one half does not match the other Border - the edges are ragged, blurred or irregular Color - the color is uneven and may include shades of black, brown and tan Diameter - there is a change in size, usually an increase Evolving - the mole has changed over the past few weeks or months Surgery is the first treatment of all stages of melanoma. Other treatments include chemotherapy and radiation, biologic, and targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

MalaCards based summary : Melanoma, also known as malignant melanoma, is related to squamous cell carcinoma, head and neck and lung cancer, and has symptoms including exanthema and pruritus. An important gene associated with Melanoma is FBN1 (Fibrillin 1), and among its related pathways/superpathways are Melanoma and MicroRNAs in cancer. The drugs Erivedge and Intron A have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and brain.

Disease Ontology : 12 A cell type cancer that has material basis in abnormally proliferating cells derives from melanocytes which are found in skin, the bowel and the eye.

Novus Biologicals : 56 Melanoma is a malignant tumor that results from uncontrolled growth of pigmented cells, called melanocytes. Several types of melanoma exist, including superficial spreading melanoma, nodular melanoma and lentigo melanoma. Melanoma diagnosis is traditionally supported by the presence of the S-100 protein marker and HMB-45, however research has determined the sensitivity and specificity of three novel antibodies as markers for melanoma: Mitf, Melan-A and tyrosinase.

PubMed Health : 63 About melanoma: We all have moles or other small lumps and bumps that are a different color to the rest of our skin. This is perfectly normal and usually nothing to worry about. It is only rarely skin cancer.Skin cancer comes in different forms. The main types are (malignant) melanoma, basal cell cancer (BCC) and squamous cell cancer (SCC). Basal cell cancer and squamous cell cancer are sometimes grouped together and referred to as non-melanoma skin cancer. Melanoma, which often looks like a very dark mole, is the most widely known type of skin cancer. This is probably because some types are dangerous and can spread very quickly throughout the body.

Wikipedia : 76 Melanoma, also known as malignant melanoma, is a type of cancer that develops from the... more...

Related Diseases for Melanoma

Diseases related to Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 787)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma, head and neck 33.4 CXCL8 MIR205 MIR221 SPRY4-IT1
2 lung cancer 32.7 BANCR CDKN2B-AS1 MIR182 MIR205 MIR221 MIR222
3 neuroblastoma 32.4 CASC15 MIR221 MIR23B MIR34A MIRLET7B
4 dermatomyositis 31.9 MIR221 MIR222 MIR34A
5 glioma 31.9 CDKN2B-AS1 MIR221 MIR222 MIR34A SPRY4-IT1
6 pancreatic cancer 31.8 CDKN2B-AS1 MIR205 MIR221 MIR222 MIR23B MIR34A
7 breast cancer 31.7 CDKN2B-AS1 MIR182 MIR193B MIR205 MIR221 MIR222
8 hepatocellular carcinoma 31.7 BANCR CASC15 CDKN2B-AS1 CXCL8 MIR182 MIR205
9 prostate cancer 31.7 CDKN2B-AS1 MIR182 MIR205 MIR221 MIR222 MIR23B
10 gastric cancer 31.6 BANCR CASC15 CDKN2B-AS1 MIR221 MIR222 MIR34A
11 glioblastoma 31.5 MIR182 MIR221 MIR222 MIR23B MIR34A
12 bladder cancer 31.3 BANCR CDKN2B-AS1 MIR205 MIR221 MIR222 MIR23B
13 leukemia, acute myeloid 31.1 CDKN2B-AS1 MIR182 MIR221 MIR222 MIR23B MIRLET7B
14 thyroid cancer, nonmedullary, 1 31.0 BANCR MIR221 MIR222 MIR34A MIRLET7B
15 oral squamous cell carcinoma 30.9 MIR221 MIR23B MIR34A
16 colorectal cancer 30.8 BANCR CDKN2B-AS1 MIR182 MIR221 MIR34A MIRLET7B
17 leukemia, chronic lymphocytic 30.7 MIR221 MIR23B MIR34A STAT1
18 cervical cancer 30.7 CDKN2B-AS1 MIR23B MIRLET7B SPRY4-IT1
19 melanoma, cutaneous malignant 1 12.4
20 acral lentiginous melanoma 12.4
21 skin melanoma 12.3
22 melanoma-pancreatic cancer syndrome 12.3
23 ocular melanoma 12.3
24 melanoma, cutaneous malignant 8 12.3
25 digestive system melanoma 12.3
26 melanoma-astrocytoma syndrome 12.2
27 nodular malignant melanoma 12.2
28 intraocular melanoma 12.2
29 amelanotic melanoma 12.2
30 mucosal melanoma 12.2
31 malignant spindle cell melanoma 12.2
32 melanoma-associated retinopathy 12.2
33 superficial spreading melanoma 12.2
34 melanoma, cutaneous malignant 2 12.1
35 melanoma, cutaneous malignant 3 12.1
36 melanoma, cutaneous malignant 5 12.1
37 melanoma, cutaneous malignant 6 12.1
38 melanoma, cutaneous malignant 9 12.1
39 melanoma, uveal 12.1
40 lentigo maligna melanoma 12.1
41 melanoma, cutaneous malignant 4 12.1
42 melanoma, cutaneous malignant 7 12.0
43 melanoma, cutaneous malignant 10 12.0
44 choroid spindle cell melanoma 12.0
45 melanoma of soft tissue 12.0
46 dysplastic nevus syndrome 12.0
47 iris spindle cell melanoma 12.0
48 posterior uveal melanoma 12.0
49 ciliary body spindle cell melanoma 12.0
50 primary melanoma of the central nervous system 12.0

Graphical network of the top 20 diseases related to Melanoma:



Diseases related to Melanoma

Symptoms & Phenotypes for Melanoma

UMLS symptoms related to Melanoma:


exanthema, pruritus

Drugs & Therapeutics for Melanoma

PubMedHealth treatment related to Melanoma: 63

After melanoma is diagnosed, the first step is usually to try to remove it surgically. If it is already advanced or metastatic tumors have developed elsewhere, surgery is combined with other treatments such as medication or radiation.

FDA approved drugs:

(show all 11)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Erivedge 18 49 VISMODEGIB Genentech January 2012
2
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
3
Keytruda 18 49 PEMBROLIZUMAB Merck September 2014
4
Mekinist 18 49 TRAMETINIB DIMETHYL SULFOXIDE GlaxoSmithKline May of 2013
5
Odomzo 18 49 SONIDEGIB PHOSPHATE Novartis Jul-15
6
Opdivo 18 49 NIVOLUMAB Bristol-Myers Squibb March 2015/ December 2014, March 2015
7
Proleukin 18 49 ALDESLEUKIN Chiron January 1998
8
Sylatron 18 49 PEGINTERFERON ALFA-2B Merck April 2011
9
Tafinlar 18 49 DABRAFENIB MESYLATE GlaxoSmithKline May 2013
10
Yervoy 18 49 IPILIMUMAB Bristol-Myers Squibb March 2011
11
Zelboraf 18 49 VEMURAFENIB Roche August of 2011

Drugs for Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 657)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4342-03-4 5351166
3
Vindesine Approved, Investigational Phase 4 59917-39-4, 53643-48-4 40839
4
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
5
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 99011-02-6 57469
6
Dabrafenib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1195765-45-7 44462760 44516822
7
Trametinib Approved Phase 4,Phase 3,Phase 2,Phase 1 871700-17-3 11707110
8
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
9
nivolumab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 946414-94-4
10
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 124-94-7 31307
11
Everolimus Approved Phase 4,Phase 2,Phase 1 159351-69-6 6442177
12
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
13
Palbociclib Approved, Investigational Phase 4,Phase 2,Phase 1 571190-30-2 11431660 5005498 5330286
14
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
15
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 284461-73-0 216239 406563
16
Sunitinib Approved, Investigational Phase 4,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
17
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 85898-30-2, 110942-02-4
18
Etanercept Approved, Investigational Phase 4 185243-69-0
19
Aminolevulinic acid Approved Phase 4,Phase 2,Not Applicable 106-60-5 137
20
Citalopram Approved Phase 4 59729-33-8 2771
21
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 60-00-4, 62-33-9 6049
22
Pentetic acid Approved Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 67-43-6
23
Simvastatin Approved Phase 4 79902-63-9 54454
24
Adalimumab Approved Phase 4 331731-18-1 16219006
25
Bortezomib Approved, Investigational Phase 4,Phase 2,Phase 1 179324-69-7 387447 93860
26
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 1 302962-49-8 3062316
27
Olaparib Approved Phase 4,Phase 1 763113-22-0 23725625
28
Ramucirumab Approved, Investigational Phase 4,Phase 2,Phase 1 947687-13-0
29
Vorinostat Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 149647-78-9 5311
30
Ceritinib Approved Phase 4,Phase 2,Early Phase 1 1032900-25-6
31
Crizotinib Approved Phase 4,Phase 2,Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
32
Gefitinib Approved, Investigational Phase 4 184475-35-2 123631
33
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
34
Lactitol Investigational Phase 4,Phase 1,Phase 2 585-86-4 3871
35
Lapatinib Approved March 2007, Investigational Phase 4,Phase 3,Phase 2 231277-92-2, 388082-78-8 208908 9941095
36 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
38 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
39 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
40 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
41 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
42 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
43 Analgesics Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
44 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
45 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
46 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 1,Phase 2,Not Applicable
47 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
48 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2
49 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
50 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2462)
# Name Status NCT ID Phase Drugs
1 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4 Cisplatin, Vindesine, Dacarbazine (drugs)
2 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
3 Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab Completed NCT01515189 Phase 4
4 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
5 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4 Fibrin Sealant (Tisseel) used in the Experimental Arm.
6 Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Completed NCT02685592 Phase 4 5-aminolevulinic acid nanoemulsion
7 Evaluating the Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment Completed NCT00352885 Phase 4 Escitalopram;Placebo;IL-2
8 A Study for Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Radical Lymph Node Dissection Completed NCT02476357 Phase 4
9 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer Completed NCT02287675 Phase 4 Lymphoseek;Sulfur Colloid
10 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4 Imiquimod
11 Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors Completed NCT00075166 Phase 4
12 Assessing the Role of "Statin" Therapy and Perioperative Inflammatory Response in Patients Undergoing Major Orthopedic Surgery Completed NCT00656292 Phase 4 Simvastatin;Placebo
13 An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation Completed NCT01644396 Phase 4
14 Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma Recruiting NCT02451488 Phase 4 GM-CSF
15 Flu Vaccine Responses in the Setting of Melanoma Treatment Recruiting NCT03315975 Phase 4
16 Dabrafenib and/or Trametinib Rollover Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
17 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
18 Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies Active, not recruiting NCT02626065 Phase 4 Nivolumab
19 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Active, not recruiting NCT02379000 Phase 4 Triamcinolone Acetonide
20 An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma Active, not recruiting NCT01898585 Phase 4 Zelboraf
21 A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. Active, not recruiting NCT02068196 Phase 4 Ipilimumab
22 Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma Not yet recruiting NCT02645149 Phase 4 Standard therapy or clinical trial;Matched targeted therapy;Trametinib and / or supportive care
23 Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1 Not yet recruiting NCT03313544 Phase 4 Nivolumab
24 HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4 vemurafenib + HD IL-2
25 HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4 High Dose Interleukin-2;Ipilimumab
26 Genetically-informed Therapies for Patients With Metastatic Cancer Withdrawn NCT02000739 Phase 4
27 Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients Unknown status NCT01861938 Phase 2, Phase 3
28 A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Dacarbazine in the Treatment of Patients With Non-Resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-Kit Unknown status NCT01280565 Phase 3 masitinib;Dacarbazine
29 Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma Unknown status NCT00002767 Phase 3
30 High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00002763 Phase 3
31 Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00006249 Phase 3
32 Vaccine Therapy in Treating Patients With Primary Stage II Melanoma Unknown status NCT00005052 Phase 3
33 Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver Unknown status NCT00039234 Phase 3 histamine dihydrochloride
34 Vaccine Therapy for Patients With Stage III Melanoma Unknown status NCT00052130 Phase 3
35 Vaccine Therapy for Patients With Stage IV Melanoma Unknown status NCT00052156 Phase 3
36 Treatment Of Radiation Retinopathy Trial Unknown status NCT00811200 Phase 2, Phase 3 ranibizumab;triamcinolone acetonide
37 Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma Unknown status NCT00002455 Phase 3
38 Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC Unknown status NCT00779714 Phase 3 DTIC (dacarbazine);paclitaxel + cisplatin;treosulfan + cytarabine
39 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
40 Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon Unknown status NCT00226408 Phase 3 Interferon-alpha-2b
41 Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel Unknown status NCT01272609 Phase 3 Timolol + LCP
42 18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology Unknown status NCT00207298 Phase 3
43 MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma Completed NCT00094653 Phase 3 MDX-010 (anti-CTLA4) monoclonal antibody
44 Nordic Adjuvant IFN Melanoma Trial Completed NCT01259934 Phase 3 Interferon-alpha2b - 1 year;Interferon-alpha2b - 2 years
45 Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma Completed NCT00002882 Phase 3 Cisplatin;Dacarbazine;Vinblastine
46 GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma Completed NCT01245062 Phase 3 GSK1120212;Chemotherapy
47 Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Completed NCT01974752 Phase 3 75mg selumetinib;placebo;Dacarbazine
48 Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267) Completed NCT00091572 Phase 3 Temozolomide;Dacarbazine
49 Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma Completed NCT00072124 Phase 3 cisplatin;dacarbazine
50 Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma Completed NCT00680225 Phase 3 Ranibizumab injection and TTT - ICG based

Search NIH Clinical Center for Melanoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: melanoma

Genetic Tests for Melanoma

Genetic tests related to Melanoma:

# Genetic test Affiliating Genes
1 Melanoma 29

Anatomical Context for Melanoma

MalaCards organs/tissues related to Melanoma:

41
Skin, T Cells, Brain, Lung, Lymph Node, Liver, Eye

Publications for Melanoma

Articles related to Melanoma:

(show top 50) (show all 13144)
# Title Authors Year
1
Association of Skin Examination Behaviors and Thinner Nodular vs Superficial Spreading Melanoma at Diagnosis. ( 29710122 )
2018
2
TR47, a PAR1-based peptide, inhibits melanoma cell migration inA vitro and metastasis inA vivo. ( 29196264 )
2018
3
Mucosal melanoma: clinical and genetic profile. ( 29797459 )
2018
4
Genome-Wide Screen for MicroRNAs Reveals a Role for miR-203 in Melanoma Metastasis. ( 29104160 )
2018
5
Capsule Commentary on Robinson et al.: A Randomized Trial on the Efficacy of Mastery Learning on Primary Care Providers' Melanoma Opportunistic Screening Skills and Practice. ( 29450688 )
2018
6
High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. ( 29975414 )
2018
7
HMGA1 and MMP-11 Are Overexpressed in Human Non-melanoma Skin Cancer. ( 29374701 )
2018
8
Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. ( 29973204 )
2018
9
Basal cell carcinoma and malignant melanoma cutaneous collision tumor. ( 29904313 )
2018
10
A Fluorescent Probe for Early Detection of Melanoma and Its Metas-tasis through Specifically Imaging Tyrosinase Activity in Mouse Model. ( 29975041 )
2018
11
Clinical patterns and management of primary mucosal melanoma: a single centre experience. ( 29388353 )
2018
12
Updates in the management of sinonasal mucosal melanoma. ( 29095708 )
2018
13
Robot-assisted laparoscopic surgery for abdominal metastatic melanoma mimicking a gastrointestinal stromal tumor: A case report and review of the literature. ( 29952974 )
2018
14
Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma. ( 29939876 )
2018
15
Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival. ( 28796414 )
2018
16
Mucosal Melanoma: a Literature Review. ( 29569184 )
2018
17
A Case of Erythema Multiforme Major Developed after Sequential Use of Two Immune Checkpoint Inhibitors, Nivolumab and Ipilimumab, for Advanced Melanoma: Possible Implication of Synergistic and/or Complementary Immunomodulatory Effects. ( 29515387 )
2018
18
Computed tomography-guided minimally invasive selective approach of an isolated retroperitoneal melanoma metastasis. ( 29154516 )
2018
19
High density of M2-macrophages in acral lentiginous melanoma compared to superficial spreading melanoma. ( 29415335 )
2018
20
Anorectal mucosal melanoma. ( 29492238 )
2018
21
Impact of Dermoscopy and Reflectance Confocal Microscopy on the Histopathologic Diagnosis of Lentigo Maligna/Lentigo Maligna Melanoma. ( 29933314 )
2018
22
HDAC6 interacts with PTPN1 to enhance melanoma cells progression. ( 29278704 )
2018
23
Title ultrasound features of ovarian melanoma metastases: The "Golf ball" aspect. ( 29198556 )
2018
24
Hepatic artery infusion of melphalan in patients with liver metastases from ocular melanoma. ( 29878390 )
2018
25
Unsuspected Amelanotic Melanoma in an Elephantiasis Foot. ( 29854646 )
2018
26
Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma. ( 29449059 )
2018
27
Interferon Signaling Is Frequently Downregulated in Melanoma. ( 29977240 )
2018
28
Recurrent vulvar melanoma invading urethra. Clinical case and literature review. ( 29888188 )
2018
29
Intermittent hypoxia promotes melanoma lung metastasis via oxidative stress and inflammation responses in a mouse model of obstructive sleep apnea. ( 29433520 )
2018
30
Plaque brachytherapy for posterior uveal melanoma in 2018: improved techniques and expanded indications. ( 29538180 )
2018
31
Malignant Melanoma Metastatic to Oligodendroglioma: Case Report and Literature Review of Tumor-to-Tumor Metastasis to Gliomas. ( 29746652 )
2018
32
Skeletal muscle and solitary bone metastases from malignant melanoma: multimodality imaging and oncological outcome. ( 29975212 )
2018
33
Pigmented purpura masquerading as acral melanoma. ( 29974454 )
2018
34
Targeted Photodynamic-Induced Singlet Oxygen Production by Peptide-Conjugated Biodegradable Nanoparticles for Treatment of Skin Melanoma. ( 29885810 )
2018
35
Correction to: Figueira et al., Primary orbital melanoma: a case series and literature review. ( 29513628 )
2018
36
Inhibition of p38 and ERK1/2 pathways by Sparstolonin B suppresses inflammation-induced melanoma metastasis. ( 29276966 )
2018
37
Primary Spinal Cord Melanoma: A Case Report and a Systemic Review of Overall Survival. ( 29614357 )
2018
38
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. ( 29449192 )
2018
39
Approaches to regional lymph node metastasis in patients with head and neck mucosal melanoma. ( 29044491 )
2018
40
The Role of Histone Deacetylase Inhibitors in Uveal Melanoma: Current Evidence. ( 29970501 )
2018
41
Adjuvant Therapy in Resected Melanoma. ( 29446285 )
2018
42
Acral lentiginous melanoma. ( 29900875 )
2018
43
Adjuvant Therapy in Resected Melanoma. ( 29446283 )
2018
44
Caspase-independent cell death does not elicit a proliferative response in melanoma cancer cells. ( 29973136 )
2018
45
Unsuspected and misdiagnosed posterior uveal melanoma following enucleation and evisceration in Ottawa-Gatineau. ( 29631828 )
2018
46
Pyoderma gangrenosum with its subtype affecting oral mucosa pyostomatitis vegetans following skin melanoma surgical excision in a patient with ulcerative colitis: a case report. ( 29760625 )
2018
47
Plant galactolipid dLGG suppresses lung metastasis of melanoma through deregulating TNF-I+-mediated pulmonary vascular permeability and circulating oxylipin dynamics in mice. ( 29978476 )
2018
48
Comparative genomics reveals that loss of lunatic fringe (LFNG) promotes melanoma metastasis. ( 29193607 )
2018
49
MART-1-Labeled Melanocyte Density and Distribution in Actinic Keratosis and Squamous Cell Cancer in situ: Pagetoid Melanocytes are a Potential Source of Misdiagnosis as Melanoma in Situ. ( 29943494 )
2018
50
Primary sinonasal mucosal melanoma simulated as cystic lesions: a case report. ( 29535967 )
2018

Variations for Melanoma

ClinVar genetic disease variations for Melanoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 FBN1 NM_000138.4(FBN1): c.5788+5G> A single nucleotide variant Pathogenic rs193922219 GRCh37 Chromosome 15, 48738898: 48738898
2 FBN1 NM_000138.4(FBN1): c.5788+5G> A single nucleotide variant Pathogenic rs193922219 GRCh38 Chromosome 15, 48446701: 48446701
3 CDKN2A NM_000077.4(CDKN2A): c.197A> C (p.His66Pro) single nucleotide variant Uncertain significance rs756750256 GRCh38 Chromosome 9, 21971162: 21971162
4 CDKN2A NM_000077.4(CDKN2A): c.197A> C (p.His66Pro) single nucleotide variant Uncertain significance rs756750256 GRCh37 Chromosome 9, 21971161: 21971161
5 BRCA2 NM_000059.3(BRCA2): c.2063A> G (p.Tyr688Cys) single nucleotide variant Uncertain significance rs28897713 GRCh38 Chromosome 13, 32336418: 32336418
6 BRCA2 NM_000059.3(BRCA2): c.2063A> G (p.Tyr688Cys) single nucleotide variant Uncertain significance rs28897713 GRCh37 Chromosome 13, 32910555: 32910555

Cosmic variations for Melanoma:

9
(show top 50) (show all 267)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM231651 PREX2 skin,leg,malignant melanoma,nodular c.2323C>T p.P775S 8:68093677-68093677 9
2 COSM231662 PREX2 skin,leg,malignant melanoma,nodular c.4127C>T p.A1376V 8:68146248-68146248 9
3 COSM231655 PREX2 skin,back,malignant melanoma,superficial spreading c.2531G>A p.G844D 8:68097179-68097179 9
4 COSM231663 PREX2 skin,back,malignant melanoma,superficial spreading c.4165G>A p.E1389K 8:68146286-68146286 9
5 COSM581 NRAS skin,leg,malignant melanoma,nodular c.181C>G p.Q61E 1:114713909-114713909 9
6 COSM1756934 NF1 skin,back,malignant melanoma,nodular c.3028C>T p.Q1010* 17:31230297-31230297 9
7 COSM25914 MLH1 skin,leg,malignant melanoma,nodular c.1732-1G>A p.? 3:37047518-37047518 9
8 COSM1651647 KIT skin,eye,malignant melanoma,NS c.1459G>A p.G487S 4:54725969-54725969 9
9 COSM476 BRAF skin,back,malignant melanoma,superficial spreading c.1799T>A p.V600E 7:140753336-140753336 9
10 COSM471 BRAF skin,back,malignant melanoma,superficial spreading c.1790T>G p.L597R 7:140753345-140753345 9
11 COSM1139 BRAF skin,back,malignant melanoma,superficial spreading c.1840T>C p.S614P 7:140753295-140753295 9
12 COSM231656 skin,back,malignant melanoma,superficial spreading c.2531G>A p.G844D 8:68097179-68097179 9
13 COSM231652 skin,leg,malignant melanoma,nodular c.2323C>T p.P775S 8:68093677-68093677 9
14 COSM10863 TP53 skin,back,malignant melanoma,NS c.833C>T p.P278L 17:7673787-7673787 8
15 COSM44026 TP53 skin,NS,malignant melanoma,superficial spreading c.559G>A p.G187S 17:7675053-7675053 8
16 COSM10867 TP53 skin,NS,malignant melanoma,nodular c.797G>A p.G266E 17:7673823-7673823 8
17 COSM43690 TP53 skin,NS,malignant melanoma,superficial spreading c.592G>A p.E198K 17:7674939-7674939 8
18 COSM10656 TP53 skin,NS,malignant melanoma,superficial spreading c.742C>T p.R248W 17:7674221-7674221 8
19 COSM5610575 RUNX1T1 skin,back,malignant melanoma,NS c.206C>T p.S69F 8:92014730-92014730 8
20 COSM5610538 RPTOR skin,back,malignant melanoma,NS c.484G>A p.G162R 17:80707976-80707976 8
21 COSM131810 ROR2 skin,back,malignant melanoma,NS c.1172T>C p.V391A 9:91730921-91730921 8
22 COSM125734 RAC1 skin,NS,malignant melanoma,nodular c.85C>T p.P29S 7:6387261-6387261 8
23 COSM142711 PTPRT skin,back,malignant melanoma,NS c.4372G>A p.E1458K 20:42080899-42080899 8
24 COSM142708 PTPRT skin,back,malignant melanoma,NS c.2779G>A p.D927N 20:42141972-42141972 8
25 COSM5610410 PTPRK skin,back,malignant melanoma,NS c.3251+2T>A p.? 6:127985719-127985719 8
26 COSM5610413 PTPRK skin,back,malignant melanoma,NS c.3894C>T p.I1298I 6:127976732-127976732 8
27 COSM142789 PTPRH skin,back,malignant melanoma,NS c.2969C>T p.P990L 19:55185595-55185595 8
28 COSM5610296 PTPRD skin,back,malignant melanoma,NS c.3487G>A p.E1163K 9:8471012-8471012 8
29 COSM142712 PTPRD skin,back,malignant melanoma,NS c.182G>A p.G61E 9:8636727-8636727 8
30 COSM142819 PTPN12 skin,back,malignant melanoma,NS c.1448C>T p.S483L 7:77627127-77627127 8
31 COSM142820 PTPN12 skin,back,malignant melanoma,NS c.2314C>T p.P772S 7:77639251-77639251 8
32 COSM5610076 PTK2B skin,back,malignant melanoma,NS c.596C>T p.S199F 8:27430137-27430137 8
33 COSM5142 PTEN skin,NS,malignant melanoma,superficial spreading c.112C>T p.P38S 10:87894057-87894057 8
34 COSM5119 PTEN skin,NS,malignant melanoma,nodular c.730C>T p.P244S 10:87957948-87957948 8
35 COSM5111 PTEN skin,upper leg,malignant melanoma,superficial spreading c.737C>T p.P246L 10:87957955-87957955 8
36 COSM6503475 PREX2 skin,NS,malignant melanoma,nodular c.1091A>T p.K364I 8:68053244-68053244 8
37 COSM231647 PREX2 skin,NS,malignant melanoma,nodular c.1994C>T p.P665L 8:68083355-68083355 8
38 COSM6503481 PREX2 skin,NS,malignant melanoma,nodular c.702G>A p.W234* 8:68030655-68030655 8
39 COSM6503482 PREX2 skin,NS,malignant melanoma,superficial spreading c.934G>A p.D312N 8:68044581-68044581 8
40 COSM231665 PREX2 skin,upper leg,malignant melanoma,superficial spreading c.4646C>T p.A1549V 8:68217657-68217657 8
41 COSM231666 PREX2 skin,NS,malignant melanoma,nodular c.4669C>T p.R1557C 8:68217680-68217680 8
42 COSM231627 PREX2 skin,upper leg,malignant melanoma,superficial spreading c.34G>T p.E12* 8:67952428-67952428 8
43 COSM3650433 PREX2 skin,NS,malignant melanoma,superficial spreading c.984G>A p.W328* 8:68053137-68053137 8
44 COSM231631 PREX2 skin,NS,malignant melanoma,nodular c.468G>A p.K156K 8:68027248-68027248 8
45 COSM231661 PREX2 skin,back,malignant melanoma,NS c.4066G>A p.E1356K 8:68138496-68138496 8
46 COSM5609955 PLCG1 skin,back,malignant melanoma,NS c.1161G>A p.K387K 20:41164145-41164145 8
47 COSM760 PIK3CA skin,back,malignant melanoma,NS c.1624G>A p.E542K 3:179218294-179218294 8
48 COSM4713314 PDGFRB skin,back,malignant melanoma,NS c.3058G>A p.D1020N 5:150117697-150117697 8
49 COSM5609727 PAK3 skin,back,malignant melanoma,NS c.1015T>C p.W339R 23:111194323-111194323 8
50 COSM1294479 PAK3 skin,back,malignant melanoma,NS c.525T>A p.D175E 23:111162971-111162971 8

Copy number variations for Melanoma from CNVD:

7 (show top 50) (show all 1973)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13791 1 1 46500000 Insertion Melanoma
2 13897 1 1007060 1041599 Amplification C1orf159 Melanoma
3 14968 1 111600000 148000000 Deletion Melanoma
4 15008 1 111800000 116100000 Gain NRAS Melanoma
5 15387 1 115048600 115061038 Gain NRAS Melanoma
6 18715 1 147200000 149200000 Ampfication SETDB1 Melanoma
7 20086 1 15300000 247249719 Insertion Melanoma
8 21281 7 92072170 92303813 Gain CDK6 Malignant melanoma
9 24543 1 182188599 196365692 Amplification ASPM Melanoma
10 24544 1 182188599 196365692 Amplification ATP6V1G3 Melanoma
11 24545 1 182188599 196365692 Amplification B3GALT2 Melanoma
12 24546 1 182188599 196365692 Amplification C1orf27 Melanoma
13 24547 1 182188599 196365692 Amplification C1orf53 Melanoma
14 24548 1 182188599 196365692 Amplification C1orf99 Melanoma
15 24549 1 182188599 196365692 Amplification CDC73 Melanoma
16 24550 1 182188599 196365692 Amplification CFH Melanoma
17 24551 1 182188599 196365692 Amplification CFHR1 Melanoma
18 24552 1 182188599 196365692 Amplification CFHR2 Melanoma
19 24553 1 182188599 196365692 Amplification CFHR3 Melanoma
20 24554 1 182188599 196365692 Amplification CFHR4 Melanoma
21 24555 1 182188599 196365692 Amplification CFHR5 Melanoma
22 24556 1 182188599 196365692 Amplification CRB1 Melanoma
23 24557 1 182188599 196365692 Amplification DENND1B Melanoma
24 24558 1 182188599 196365692 Amplification F13B Melanoma
25 24559 1 182188599 196365692 Amplification FAM5C Melanoma
26 24560 1 182188599 196365692 Amplification GLRX2 Melanoma
27 24561 1 182188599 196365692 Amplification HMCN1 Melanoma
28 24562 1 182188599 196365692 Amplification KCNT2 Melanoma
29 24563 1 182188599 196365692 Amplification LHX9 Melanoma
30 24564 1 182188599 196365692 Amplification NEK7 Melanoma
31 24565 1 182188599 196365692 Amplification OCLM Melanoma
32 24566 1 182188599 196365692 Amplification PDC Melanoma
33 24567 1 182188599 196365692 Amplification PLA2G4A Melanoma
34 24568 1 182188599 196365692 Amplification PRG4 Melanoma
35 24569 1 182188599 196365692 Amplification PTGS2 Melanoma
36 24570 1 182188599 196365692 Amplification PTPRC Melanoma
37 24571 1 182188599 196365692 Amplification RGS1 Melanoma
38 24572 1 182188599 196365692 Amplification RGS13 Melanoma
39 24573 1 182188599 196365692 Amplification RGS18 Melanoma
40 24574 1 182188599 196365692 Amplification RGS2 Melanoma
41 24575 1 182188599 196365692 Amplification RGS21 Melanoma
42 24576 1 182188599 196365692 Amplification TPR Melanoma
43 24577 1 182188599 196365692 Amplification TROVE2 Melanoma
44 24578 1 182188599 196365692 Amplification UCHL5 Melanoma
45 24579 1 182188599 196365692 Amplification ZBTB41 Melanoma
46 26238 1 198304656 198310281 Deletion Melanoma
47 29172 1 228366540 228914590 LOH Melanoma
48 29295 1 2300000 46500000 Insertion Melanoma
49 29296 1 2300000 46500000 Insertion Melanoma
50 30306 1 241700000 247249719 Insertion Melanoma

Expression for Melanoma

Search GEO for disease gene expression data for Melanoma.

Pathways for Melanoma

Pathways related to Melanoma according to KEGG:

37
# Name Kegg Source Accession
1 Melanoma hsa05218

Pathways related to Melanoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.64 MIR193B MIR205 MIR221 MIR222 MIR23B MIR34A
2 10.83 MIR221 MIR222 MIR23B

GO Terms for Melanoma

Cellular components related to Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 CCL27 CXCL8 FBN1 MIR182 MIR205 MIR221

Biological processes related to Melanoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of angiogenesis GO:0016525 9.7 MIR222 MIR34A STAT1
2 negative regulation of sprouting angiogenesis GO:1903671 9.58 MIR221 MIR23B MIR34A
3 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.51 MIR221 MIR222
4 positive regulation of erythrocyte differentiation GO:0045648 9.5 MIR221 MIR222 STAT1
5 positive regulation of axon regeneration GO:0048680 9.49 MIR221 MIR222
6 negative regulation by host of viral genome replication GO:0044828 9.48 MIR221 MIR222
7 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.46 MIR221 MIR222
8 negative regulation of cell adhesion molecule production GO:0060354 9.43 MIR221 MIR222
9 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.37 MIR221 MIR222
10 positive regulation of Schwann cell migration GO:1900149 9.26 MIR221 MIR222
11 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.16 MIR221 MIR222
12 gene silencing by miRNA GO:0035195 9.02 MIR221 MIR222 MIR23B MIR34A MIRLET7B
13 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 8.96 MIR221 MIR222

Molecular functions related to Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.02 MIR221 MIR222 MIR23B MIR34A MIRLET7B

Sources for Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....